Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT03334487 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Strategic considerations

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Dexamethasone
DRUG: Rovalpituzumab tesirine

Sponsor

AbbVie